Perspectives

Prime’s missed refill program is a hit with Medicare plans

Two-touch rapid response program helped more members

August 19, 2018

Two-touch rapid response program helped more members to refill their prescriptions

Prime’s missed refill program was tested with nearly 83,000 Medicare members who had at least a seven-day gap in a CMS Star-adherence medication supply. First, members first got a phone call. Then, within one or two weeks, they got a reminder letter. The adherence rate for the members in the refill program rose 8%.

Read more

Can Lowering Generics Member Cost Share Impact CMS Star Adherence Metrics? (Spring 2018)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

April 24, 2024

Prime/MRx resident wins AMCP Foundation Best Poster Award

Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes

Read More

Perspectives

April 23, 2024

Expert Clinical Network Insights: April 2024

A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

Read More

Perspectives

April 23, 2024

April Fraud Focus – How to prioritize drug safety at home  

While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…

Read More
View all news